Eskil Elmer - NeuroVive Pharmaceutical Insider

NVP -- Sweden Stock  

SEK 2.24  2.81  55.64%

Mr. Eskil Elmer has served as Chief Scientific Officer at NeuroVive Pharmaceutical AB since 2000. He was Member of the Company Board of Directors from May 2010 until June 8, 2012. Previously, he acted as the Company Chief Executive Officer from 2007 until May 2010, and he also served on the Company Board of Directors between 2000 and 2008. Eskil Elmer is Physician and Associate Professor of experimental neurology. He holds Medical degree and Doctorate of Philosophy degree from Lunds universitet. He is one of the Founders of the Company. He serves as Board member of Maas Biolab LLC and Restorative Neurosurgery Foundation .
Age: 45  Executive Since 2012  Ph.D    
46 4 62 75 62 20

Management Efficiency

The company has return on total asset (ROA) of (30.01) % which means that it has lost $30.01 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (52.78) % meaning that it generated substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

NeuroVive Pharmaceutical AB engages in the research and development of mitochondrial medicine in Sweden and internationally. NeuroVive Pharmaceutical AB was founded in 2000 and is headquartered in Lund, Sweden. NeuroVive Pharmaceutical operates under Drug Manufacturers - Major classification in Sweden and traded on Stockholm Stock Exchange. It employs 9 people.NeuroVive Pharmaceutical AB (NVP) is traded on Stockholm Stock Exchange in Sweden. It is located in Medicon Village and employs 9 people.

NeuroVive Pharmaceutical Leadership Team

Eskil Elmer, Chief Scientific Officer
Carl Olsson, Director
Michele Tavecchio, Senior Scientist
David LaskowPooley, Director
Anna Bernsten, Director
Gregory Batcheller, Executive Chairman of the Board
Denise Goode, Director
Jan Tornell, Director
Marcus Keep, Director
Ingmar Rentzhog, Investor Relations Contact Officer
Catharina Johansson, CFO
Daniel Schale, Director - Communications
Arne Ferstad, Director
Helena Levander, Independent Director
Jan Nilsson, Interim CEO and COO
Erik Kinnman, CEO
Helmuth Moltke, Independent Director
Magnus Hansson, Chief Medical Officer
Cecilia Hofvander, Investor Relations and Communications Director
Boel Flodgren, Director
Christine Tadgell, IR Officer
David Bejker, Director

Stock Performance Indicators

Did you try this?

Run Equity Analysis Now

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Equity Analysis

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Crypto Portfolio Optimizer module to optimize portfolio of digital coins and token across multiple currency and exchanges.